Equities research analysts expect ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to report earnings of ($0.12) per share for the current quarter, according to Zacks. Four analysts have made estimates for ZIOPHARM Oncology’s earnings, with the lowest EPS estimate coming in at ($0.14) and the highest estimate coming in at ($0.10). ZIOPHARM Oncology posted earnings per share of ($0.13) during the same quarter last year, which indicates a positive year-over-year growth rate of 7.7%. The business is expected to issue its next quarterly earnings results on Monday, July 30th.
On average, analysts expect that ZIOPHARM Oncology will report full-year earnings of ($0.52) per share for the current year, with EPS estimates ranging from ($0.56) to ($0.45). For the next financial year, analysts expect that the company will report earnings of ($0.41) per share, with EPS estimates ranging from ($0.53) to ($0.22). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that that provide coverage for ZIOPHARM Oncology.
ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings results on Thursday, May 10th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). The firm had revenue of $0.15 million during the quarter, compared to analyst estimates of $1.55 million.
A number of equities analysts have recently issued reports on the company. ValuEngine raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. BidaskClub raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. Zacks Investment Research downgraded ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, May 16th. Finally, HC Wainwright reissued a “buy” rating and set a $5.50 price target on shares of ZIOPHARM Oncology in a research report on Monday, May 14th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $5.25.
Institutional investors and hedge funds have recently bought and sold shares of the company. G&S Capital LLC bought a new position in shares of ZIOPHARM Oncology during the 4th quarter worth $125,000. Metropolitan Life Insurance Co. NY bought a new position in shares of ZIOPHARM Oncology during the 4th quarter worth $139,000. Teacher Retirement System of Texas boosted its position in ZIOPHARM Oncology by 302.7% during the fourth quarter. Teacher Retirement System of Texas now owns 42,517 shares of the biotechnology company’s stock valued at $176,000 after purchasing an additional 31,958 shares in the last quarter. LPL Financial LLC boosted its position in ZIOPHARM Oncology by 257.1% during the fourth quarter. LPL Financial LLC now owns 46,343 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 33,366 shares in the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. boosted its position in ZIOPHARM Oncology by 134.1% during the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 60,635 shares of the biotechnology company’s stock valued at $251,000 after purchasing an additional 34,739 shares in the last quarter. 39.78% of the stock is currently owned by institutional investors and hedge funds.
ZIOPHARM Oncology opened at $3.02 on Monday, according to Marketbeat Ratings. ZIOPHARM Oncology has a 12-month low of $2.92 and a 12-month high of $6.67. The firm has a market cap of $437.94 million, a PE ratio of -5.70 and a beta of 1.70.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.
Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.